BTN News: As global health concerns fluctuate, it’s essential to stay informed about the latest developments in infectious diseases. Recently, the Ministry of Health and Social Protection of Colombia confirmed that the clade Ib variant of the Mpox virus has not been detected in the Americas, including Colombia. This announcement provides some reassurance amidst growing global concerns about this variant. The Ministry, in coordination with the Pan American Health Organization (PAHO) and the World Health Organization (WHO), has emphasized that there is currently no need for mass vaccination or heightened border controls in the country. However, they continue to monitor the situation closely and are prepared to implement necessary measures as new directives emerge.
At this time, the Ministry of Health is urging the public to stay informed through official channels and avoid misinformation. Minister Guillermo Alfonso Jaramillo highlighted the importance of this approach, noting that while Colombia remains vigilant, there is no immediate cause for alarm regarding the clade Ib variant of Mpox in the country.
Globally, the situation in Africa regarding Mpox has prompted health systems worldwide to remain on high alert. Despite the concern, health experts have stated that the current scenario is far from leading to a new pandemic. The focus, instead, is on enhancing public awareness, especially in at-risk populations and healthcare workers. By improving early recognition of Mpox symptoms, the chances of controlling its spread increase significantly.
In Colombia, health authorities have reiterated the importance of infection prevention and control measures among healthcare professionals. These include the use of personal protective equipment (PPE), proper hand hygiene, and adherence to protocols when treating potential cases. The Ministry of Health has outlined a robust plan in line with WHO recommendations to ensure that the country is prepared to handle any developments related to Mpox effectively.
Among the key actions being taken are the reinforcement of specific risk communication strategies, coordination with PAHO to secure vaccine availability within a targeted plan, and intensified public health surveillance of rash-related illnesses. The Ministry is also strengthening capabilities for Mpox detection, diagnosis, and treatment, alongside enhancing laboratory and genomic surveillance efforts led by the National Institute of Health (INS).
Moreover, the Ministry participated in an extraordinary committee on Port Health on August 23, involving various agencies such as Migration Colombia, the Ministries of Defense and Labor, and other national entities. The discussions focused on recommendations for travelers by air and sea, enhancing surveillance at entry points, verifying emergency and contingency plans, and ensuring clear risk communication. This includes coordination among various sectors to ensure immediate response preparedness, contact tracing, and health status reporting for travelers.
So far in 2024, Colombia has identified 113 cases of Mpox linked to the clade II genetic variant, with only one active case remaining. These cases have been reported by local health entities, and thankfully, no fatalities have been associated with the virus in the country this year. It is important to note that Mpox can be transmitted not only through direct contact with bodily fluids but also through close contact with infected wildlife, intimate or sexual contact with infected individuals, or contact with contaminated materials. According to the WHO, immunosuppression is a significant risk factor for developing severe and potentially fatal forms of Mpox.
As the situation evolves, staying informed through reliable sources and adhering to health guidelines remains crucial for public safety. The Ministry of Health’s proactive approach and close collaboration with international health organizations aim to ensure that Colombia remains prepared for any future challenges related to Mpox.
